Adaptive Biotechnologies Co. (NASDAQ:ADPT) SVP Stacy L. Taylor sold 4,166 shares of the company’s stock in a transaction that occurred on Friday, April 30th. The stock was sold at an average price of $41.93, for a total transaction of $174,680.38. Following the sale, the senior vice president now directly owns 16,078 shares of the company’s stock, valued at approximately $674,150.54. The sale was disclosed in a filing with the SEC, which is available at the SEC website.
Shares of NASDAQ:ADPT opened at $38.02 on Tuesday. The company has a market cap of $5.32 billion, a price-to-earnings ratio of -40.02 and a beta of 0.35. The firm has a 50 day simple moving average of $41.51 and a 200 day simple moving average of $51.60. Adaptive Biotechnologies Co. has a one year low of $30.43 and a one year high of $71.25.
Adaptive Biotechnologies (NASDAQ:ADPT) last issued its quarterly earnings data on Tuesday, February 23rd. The company reported ($0.33) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.29) by ($0.04). The company had revenue of $30.19 million during the quarter, compared to the consensus estimate of $27.08 million. Adaptive Biotechnologies had a negative net margin of 132.32% and a negative return on equity of 20.15%. As a group, equities analysts predict that Adaptive Biotechnologies Co. will post -1.08 earnings per share for the current fiscal year.
A number of analysts have recently weighed in on ADPT shares. BTIG Research upped their price target on shares of Adaptive Biotechnologies from $66.00 to $74.00 and gave the stock a “buy” rating in a report on Tuesday, January 19th. The Goldman Sachs Group reaffirmed a “neutral” rating and set a $63.00 price target (down previously from $74.00) on shares of Adaptive Biotechnologies in a report on Tuesday, March 9th. Zacks Investment Research downgraded shares of Adaptive Biotechnologies from a “hold” rating to a “sell” rating in a report on Tuesday, January 12th. Finally, Morgan Stanley upped their price target on shares of Adaptive Biotechnologies from $46.00 to $60.00 and gave the stock an “equal weight” rating in a report on Thursday, March 4th. One analyst has rated the stock with a sell rating, two have assigned a hold rating and four have assigned a buy rating to the company’s stock. Adaptive Biotechnologies currently has an average rating of “Hold” and a consensus target price of $59.33.
Hedge funds have recently added to or reduced their stakes in the company. Private Capital Group LLC raised its stake in shares of Adaptive Biotechnologies by 1,266.7% during the first quarter. Private Capital Group LLC now owns 615 shares of the company’s stock valued at $25,000 after acquiring an additional 570 shares during the last quarter. Exchange Traded Concepts LLC bought a new position in shares of Adaptive Biotechnologies during the fourth quarter valued at $26,000. HM Payson & Co. bought a new position in shares of Adaptive Biotechnologies during the third quarter valued at $30,000. NEXT Financial Group Inc bought a new position in shares of Adaptive Biotechnologies during the fourth quarter valued at $33,000. Finally, Rothschild Investment Corp IL bought a new position in shares of Adaptive Biotechnologies during the first quarter valued at $201,000. 80.80% of the stock is owned by hedge funds and other institutional investors.
Adaptive Biotechnologies Company Profile
Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunoSEQ research service and kit that is used to answer translational research questions, as well as to discover new prognostic and diagnostic signals; and T-Detect COVID for the confirmation of past COVID-19 infection.
Further Reading: What is Elliott Wave theory?
Receive News & Ratings for Adaptive Biotechnologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adaptive Biotechnologies and related companies with MarketBeat.com's FREE daily email newsletter.